Specialized Disclosure Report (sd)
May 15 2017 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM SD
Specialized Disclosure Report
NEKTAR
THERAPEUTICS
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
455 Mission Bay Boulevard South
San Francisco, California
|
|
94158
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Mark A. Wilson
Vice President and General Counsel
(415) 482-5300
(Name and
telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to
indicate the rule pursuant to which this form is being filed, and provide the period to which the information in the form applies:
☒
|
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2015 to December 31, 2016.
|
Section 1 Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
This Form SD is filed by Nektar Therapeutics (the Company) pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as
amended, for the reporting period January 1, 2015 to December 31, 2016.
A copy of the Companys Conflict Minerals Report is provided as
Exhibit 1.01 to this Form SD, and is publicly available on the Companys website at
www.nektar.com
under the heading Investors within the Financials & Filings tab.
Item 1.02 Exhibit
The Conflict Minerals Report
required by Items 1.01 and 1.02 is filed as Exhibit 1.01 to this Form SD.
Section 2 Exhibits
Item 2.01 Exhibits
Exhibit 1.01 Conflict
Minerals Report as required by Items 1.01 and 1.02 of this Form SD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
NEKTAR THERAPEUTICS
|
|
|
|
Date: May 15, 2017
|
|
|
|
/s/ Mark A. Wilson
|
|
|
|
|
Mark A. Wilson
|
|
|
|
|
Vice President and General Counsel
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2023 to Apr 2024